Varicella-zoster virus, or VZV, is a single pathogen responsible for two distinct diseases at different stages of life: chickenpox on first exposure and shingles if the virus reawakens years or decades later. What makes VZV unusual among common infections is that recovering from chickenpox does not clear the virus from your body. Instead, VZV retreats into nerve cells, where it can persist silently for a lifetime, waiting for an opportunity to resurface. Understanding this dual nature explains why a childhood rash and a painful adult condition are really two chapters of the same infection.
How Chickenpox Happens
Chickenpox is extremely contagious. The virus typically spreads through respiratory droplets or direct contact with the fluid inside the characteristic blisters. In rare instances, surface contamination may also play a role in transmission.1PubMed Central. Case Report: A Case Report: Chickenpox Acquired Through Surface Contamination: A Rare Clincal Observation After an incubation period of roughly two weeks, the primary infection produces the familiar centrally distributed blistering rash packed with infectious virus. That cell-free virus in the blisters does double duty: it spreads to other people, and it infects sensory nerve endings in the skin.2PubMed Central. The Biology of Varicella-Zoster Virus Replication in the Skin Those infected nerve endings become the highway VZV uses to travel inward, toward the clusters of nerve cell bodies along the spine and skull where it will eventually settle in for the long haul.
The Virus Goes Into Hiding
Once the chickenpox rash clears, VZV has already established lifelong latency in sensory and autonomic ganglia, the bundles of nerve cells that relay signals between the body and the spinal cord or brain.2PubMed Central. The Biology of Varicella-Zoster Virus Replication in the Skin During this quiet phase, the virus stops making new copies of itself, stops assembling new viral particles, and dramatically reduces the amount of its genetic material in each cell. Research in human dorsal root ganglia has shown that this transition to latency happens within about four to eight weeks after the initial infection and does not require the immune system to force it; the virus essentially winds itself down on its own.3PubMed Central. Varicella-zoster virus infection of human dorsal root ganglia in vivo
Latent VZV resides mainly inside neurons, with less frequent infection of the surrounding satellite cells. Even in this dormant state, a handful of viral genes remain active, and unlike some related herpesviruses, VZV actually produces detectable proteins during latency.4PubMed. Varicella-zoster virus latency in human ganglia Those low-level gene products are thought to help the virus maintain its foothold without triggering an all-out immune response. From the outside, you would never know the virus was there. Inside those ganglia, it is quietly maintaining just enough molecular machinery to reactivate when conditions allow.
Why Shingles Happens
The immune system, specifically the cellular arm of it involving T cells, is what keeps latent VZV in check. As people age, T cells specific to VZV decline in both number and function. This age-related erosion of immune surveillance is a major reason shingles becomes more common after about age 50.5PubMed. Immune senescence But aging is not the only trigger. Anything that weakens cellular immunity can open the door: chemotherapy, organ transplant medications, HIV, high-dose corticosteroids, or severe stress. Once VZV-specific immune control drops below a critical threshold, the virus reactivates in a ganglion and travels back down the sensory nerve to the patch of skin that nerve serves.6PubMed. Reactivation of herpes zoster infection by varicella-zoster virus
What Shingles Looks and Feels Like
Shingles typically announces itself with pain, burning, or tingling in a band-like strip on one side of the body before any rash appears. This prodromal pain can last several days and occasionally fools people into thinking they have a pulled muscle or even a heart problem if it hits the chest. Then a blistering rash erupts along the path of a single nerve, forming the characteristic belt-like pattern that wraps around one side of the torso, face, or occasionally an arm or leg. The rash follows the same territory, or dermatome, supplied by the affected nerve.7Mayo Clinic Proceedings. Herpes Zoster (Shingles) and Postherpetic Neuralgia
For most people the rash crusts over and heals within two to four weeks. But in a significant minority, the pain does not leave with the rash. When pain persists for three months or more after the skin has healed, the condition is called postherpetic neuralgia, and it can be debilitating.
Postherpetic Neuralgia
Postherpetic neuralgia is the most common complication of shingles, and the pain arises not from lingering virus but from the damage VZV inflicted on nerves during reactivation. The immune and inflammatory response that fights off the reactivated virus can injure both peripheral nerve fibers and central neurons. Damaged nerve fibers develop a lower threshold for firing, sometimes discharging spontaneously or responding out of proportion to a stimulus. The result is three recognizable types of pain: a constant burning or aching, intermittent stabbing or electric-shock sensations, and exaggerated pain from normally gentle stimuli like clothing brushing the skin.8PubMed Central. Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology
Neurophysiological testing has shown that postherpetic neuralgia damages all categories of sensory nerve fibers. The constant burning pain correlates with loss of the small nerve fibers that normally carry pain signals, while the shooting, paroxysmal pain appears linked to damage in larger myelinated fibers.9PubMed. Pathophysiology of pain in postherpetic neuralgia: a clinical and neurophysiological study This means the pain is not one uniform problem but involves several distinct mechanisms, which helps explain why treating it often requires combinations of medications rather than a single approach.
Complications Beyond Pain
Shingles can cause serious trouble when the virus reactivates in certain cranial nerve ganglia rather than spinal ones. Three complications in particular deserve attention.
Herpes Zoster Ophthalmicus
When VZV reactivates in the first branch of the trigeminal nerve, the rash and inflammation hit the forehead and eye. Common eye problems include conjunctivitis, inflammation of the cornea, and uveitis (inflammation inside the eye). Rarer but more serious outcomes include optic nerve damage and retinal infection.10PubMed Central. Herpes Zoster Ophthalmicus: Presentation, Complications, Treatment, and Prevention In a large study of patients with ophthalmic shingles, nearly half developed uveitis, typically about ten days after the rash appeared. Those who developed uveitis had significantly higher rates of corneal scarring, elevated eye pressure, glaucoma, and vision loss. Prompt antiviral treatment was linked to lower rates of moderate vision loss.11PubMed. Herpes Zoster Ophthalmicus Uveitis: Onset and Complications
Ramsay Hunt Syndrome
When VZV reactivates in the geniculate ganglion near the ear, it can cause Ramsay Hunt syndrome: a triad of painful blisters in or around the ear, ear pain, and facial paralysis on the affected side.12PubMed Central. Ramsay Hunt Syndrome: An Introduction, Signs and Symptoms, and Treatment Because of nerve connections between cranial and cervical nerves, the rash can sometimes extend to areas of skin that seem unrelated to the ear, making diagnosis tricky.13PubMed Central. Ramsay Hunt Syndrome: A diagnostic dilemma Full recovery of facial movement is less likely in Ramsay Hunt syndrome than in Bell’s palsy, so early recognition and antiviral treatment matter.
VZV Vasculopathy and Stroke
Perhaps the least expected complication: VZV can infect blood vessels in the brain. After reactivation, particularly from the trigeminal ganglion, the virus can spread along nerve fibers into the walls of cerebral arteries. Once inside, it causes inflammation throughout all layers of the vessel, thickening the inner lining and disrupting the elastic layer. The result can be narrowing or blockage of brain arteries, leading to stroke. This process can occur even without a visible rash, making it difficult to recognize.14PubMed Central. Varicella Zoster Virus: A Not Uncommon Cause of Stroke in Children and Adults
VZV During Pregnancy
Chickenpox during pregnancy carries risks that go beyond the discomfort of the rash. Maternal varicella pneumonia is the most dangerous complication for the mother. For the fetus, the timing of infection matters. First-trimester chickenpox does not appear to increase the risk of miscarriage, but infection during the first or second trimester can lead to congenital varicella syndrome.15PubMed Central. Varicella Zoster Virus Infection and Pregnancy: An Optimal Management Approach This syndrome, which occurs in roughly 2% of cases where the mother is infected in the first 20 weeks, can cause skin scarring in nerve-territory patterns, neurological problems, eye disease, and skeletal abnormalities. About 30% of infants born with these signs died in the first months of life in reported cases.16Journal of Perinatology. The Congenital Varicella Syndrome Maternal infection very close to delivery poses a separate risk: the newborn may develop severe neonatal varicella before the mother’s antibodies have had time to transfer.17PubMed Central. Varicella-zoster virus (chickenpox) infection in pregnancy
Antiviral Treatment
The main antiviral drugs used against VZV, including acyclovir, valacyclovir, and famciclovir, all work by exploiting a viral enzyme to get activated inside infected cells, then jamming the machinery VZV needs to copy its DNA.18PubMed. Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment Because they share this mechanism, a virus that develops resistance to one is typically resistant to the others as well, though resistance is uncommon outside severely immunocompromised patients.
Timing matters. The conventional wisdom is that antivirals work best when started within 72 hours of the rash appearing, but clinical trial data show meaningful benefit even when treatment is delayed. In trials comparing acyclovir to placebo, patients who started treatment within 48 hours saw their pain resolve in about 28 days versus about 62 days on placebo. Even patients who started treatment between 48 and 72 hours still resolved pain faster. Valacyclovir outperformed acyclovir at both time windows.19PubMed. Treatment of acute herpes zoster: effect of early (< 48 h) versus late (48-72 h) therapy with acyclovir and valaciclovir on prolonged pain The practical takeaway: if you develop shingles, starting antivirals sooner is better, but do not skip them just because a couple of days have passed.
The Chickenpox Vaccine
The live attenuated varicella vaccine traces back to the work of Dr. Michiaki Takahashi in Japan in the early 1970s. The vaccine strain, called Oka after the child from whom the virus was originally isolated, was first shown to work in 1974 when it prevented chickenpox in children on a hospital ward who had been exposed to the virus.20PubMed. Development of varicella vaccine in Japan and future prospects Decades of follow-up confirmed that the vaccine is well tolerated and provides long-term immunity in both healthy and high-risk individuals.21PubMed. 25 years’ experience with the Biken Oka strain varicella vaccine: a clinical overview
No vaccine is perfect, and a ten-year follow-up of vaccinated children in Japan found that about one in five developed a mild “breakthrough” case of chickenpox after later exposure, though their symptoms were considerably milder than in unvaccinated children. A very small fraction, less than 1%, developed shingles in the years after vaccination, confirming that the vaccine strain itself can establish latency and later reactivate, though this appears to be uncommon.22PubMed. Experience with live attenuated varicella vaccine (Oka strain) in healthy Japanese subjects; 10-year survey at pediatric clinic
The Shingles Vaccine
For preventing shingles in older adults, the original live zoster vaccine (Zostavax) was the first to prove the concept that boosting VZV-specific immunity could reduce shingles risk. However, its effectiveness waned over time and it could not be given to immunocompromised patients because it contained live virus. The recombinant zoster vaccine (Shingrix) solved both problems by using a single VZV protein combined with an adjuvant rather than live virus, allowing it to generate a strong immune response even in people with weakened immune systems.23PubMed Central. Recombinant zoster vaccine (Shingrix®): a new option for the prevention of herpes zoster and postherpetic neuralgia Most economic evaluations have found the recombinant vaccine to be cost-effective, and modeling suggests that vaccination starting around age 60 offers the best balance of public health benefit and cost.24PubMed Central. Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review25PubMed Central. Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old
Does Less Chickenpox Mean More Shingles?
One of the more counterintuitive debates in VZV epidemiology is whether widespread childhood chickenpox vaccination could inadvertently increase shingles rates in adults. The idea is straightforward: adults who had chickenpox as children periodically encounter children with active chickenpox, and that re-exposure gives their immune system a natural boost against VZV. Adults living with children appear to have meaningfully lower rates of shingles, consistent with this exogenous boosting hypothesis. Modeling work has estimated that such re-exposure boosts VZV-specific immunity for an average of about 20 years.26PubMed. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox
If those boosts disappear because fewer children are getting chickenpox, adults might lose a form of passive immune maintenance they never knew they were receiving. However, real-world data from the United States have been more reassuring. Shingles rates were already climbing before the varicella vaccine was introduced, rising about 39% between 1992 and 2010, and the rate of increase did not speed up after mass childhood vaccination began. State-level vaccination coverage showed no link to local shingles incidence.27PubMed Central. Examination of links between herpes zoster incidence and childhood varicella vaccination The upward trend in shingles may have more to do with aging populations, increased awareness and diagnosis, and rising rates of immunosuppressive therapy than with any loss of exogenous boosting. The debate is not settled, but the worst-case predictions of a massive shingles epidemic triggered by the chickenpox vaccine have not materialized.
Shingles Vaccination and Dementia Risk
An intriguing and still-developing line of research connects VZV vaccination to brain health. A large study found that people who received the recombinant shingles vaccine had a lower risk of being diagnosed with dementia in the six years following vaccination. The association translated to roughly 164 additional days lived without a dementia diagnosis among those who eventually developed the condition, amounting to about a 17% increase in diagnosis-free time. The effect held up across multiple analyses and was present in both men and women, though it was stronger in women. The recombinant shingles vaccine was also associated with lower dementia risk than influenza and tetanus-diphtheria-pertussis vaccines, which helps rule out a generic “healthy vaccinee” effect.28PubMed Central. The recombinant shingles vaccine is associated with lower risk of dementia
This does not prove that preventing VZV reactivation prevents dementia. But there is a plausible biological connection: VZV vasculopathy, described earlier, can damage blood vessels in the brain, and chronic low-grade inflammation from herpesvirus reactivation has been linked to neurodegeneration in animal and observational studies. Whether this will eventually lead to shingles vaccination being recommended partly for brain protection is far too early to say, but the signal is strong enough that researchers are pursuing it seriously.
An Ancient Virus With a Human History
VZV is not just a modern nuisance; it has been with our species for an extraordinarily long time. The ancestral virus likely coevolved with primates in Africa. When anatomically modern humans migrated out of Africa roughly 60,000 years ago, VZV traveled with them, sitting latent in the dorsal root ganglia of every carrier. Today the virus is classified into five major genetic clades, and their geographic distribution maps loosely onto human migration patterns, with some clades found primarily in Asia and others in Europe.29PubMed Central. Pangaea and the Out-of-Africa Model of Varicella-Zoster Virus Evolution and Phylogeography Some phylogenetic analyses have complicated this picture, suggesting that currently circulating VZV strains may have a more recent European origin rather than a straightforward out-of-Africa narrative.30The Journal of Infectious Diseases. Possible European Origin of Circulating Varicella Zoster Virus Strains
VZV’s close relative, simian varicella virus, causes a strikingly similar disease in Old World monkeys: a primary rash that resolves, latency in ganglia, and the potential for later reactivation as a zoster-like illness.31PubMed Central. Simian varicella in old world monkeys In laboratory settings, rhesus macaques infected with simian varicella virus develop a disease that closely mimics human chickenpox, including the same pattern of latent gene expression in ganglia afterward. Even the specific genes that remain active during latency overlap between the simian and human viruses.32PLoS Pathogens. Simian Varicella Virus Infection of Rhesus Macaques Recapitulates Essential Features of Varicella Zoster Virus Infection in Humans This deep conservation across primate species suggests that the latency-reactivation strategy is not a bug in VZV’s design. It is the core feature that has allowed the virus to persist across millions of years of host evolution, quietly riding along in nerve cells from one generation’s epidemic to the next.